In the past ten years, Maixin has been adhering to the concept of "being professional, realistic and enterprising", and has always been committed to providing users with high-quality products synchronized with the world, and has established the first immunohistochemical quality control laboratory in China, which has effectively promoted the development of pathology and biology in China. Unique academic marketing, strictly controlled product quality and perfect after-sales service have made Maixin one of the most important suppliers of biomedical reagents in China, ranking first in the domestic market share of immunohistochemical reagents for many years.
The full completion of the human genome project marks that we are about to enter a new era of biology. Maixin will, as always, provide China scientists with high-quality products and all-round technical support and services, and make its own contribution to human health. 1In March, 1993, Maixin Company was established in Hongshan Science Park, Fuzhou with a registered capital of 500,000 yuan.
1994 1 month, the ready-to-use immunohistochemical antibody was introduced for the first time in China;
1June, 1994, the ready-to-use SP enzyme-labeled kit was first introduced, and the shelf life reached 12 months, reaching the international advanced level.
From April, 65438 to April, 0994, the national pathology new technology and progress jointly organized by China Pathology Society and Journal of Chinese Pathology Society was held in Fuzhou for the first time.
Seminars and immunohistochemical chemical technology courses ";
1995 Chen Nianxin Company won the honorary title of "Fujian High-tech Enterprise";
1996 laoxin company was invited to attend the first national symposium on immunohistochemical standards held in Beijing and made a speech at the conference;
1May, 1997, initiated and participated in the publication of the first diagnostic monograph of immunohistochemistry, Diagnostic Immunohistochemistry;
1998, Laoxin Company established a website and registered Chinese and English domain names, and also registered two English domain names of "Immunohistochemistry" and "Antibody2", which significantly improved the click-through rate of the company's website.
1999 The aging new trademark has been successfully registered by the State Trademark Office and protected by national laws (the registration number is1285019);
In September, 2000, former Fujian Provincial Party Secretary Chen, Vice Governor Pan Xincheng and other provincial and municipal leaders inspected Maixin Company and highly affirmed its development.
200 1 reached a strategic alliance with LabVision, the world's largest supplier of immunohistochemical automation instruments;
In 200 1 year, Chen Xin Company published the first color immunohistochemical antibody catalogue in the industry, which has been published continuously to the fifth volume.
In 2002, the National Immunohistochemical Staining Competition sponsored by Maixin Company was held in Wuyishan, Fujian.
In 2003, the company successfully injected capital with a registered capital of 3.5 million yuan.
In 2003, rabbit monoclonal antibody immunohistochemical reagent was introduced and developed for the first time in China.
In 2003, Wang, the general manager of the old and new companies, led the heads of relevant departments of the company to visit the United States and formed a strategic alliance with LabVision.
In 2003, Laoxin Company fully funded the founding meeting of CCP (China Pathologist Working Committee) held in Hainan.
In 2005, in cooperation with foreign laboratories, a polymer-based non-biotin immunohistochemical enzyme-labeled amplification system was successfully developed.
In 2006, it was funded by the Innovation Fund for Small and Medium-sized Enterprises of the Ministry of Science and Technology, and the prostate double-staining three-label detection kit was praised by experts.
In August 2006, the "Pathology Forum at Home and Abroad" sponsored by Maixin Company was held in Fuzhou.
In 2007, Max007, an immunohistochemical amplification system with high magnification and high sensitivity, which was created by Laoxin Company, was successfully developed.
In 2007, the first color immunohistochemical monograph "Immunohistochemical Pathological Diagnosis" in China was published by Maixin Company.
In 2007, the purification laboratory of Laoxin Company was completed, and the GMP transformation system successfully passed the certification of Fujian American Food and Drug Administration.
In July, 2007, Maixin Company 13 immunohistochemical kit passed the test of China Institute for Drug and Biological Products for the first time in China.
In June 2007, 165438+ 10, the company successfully increased its capital again with a registered capital of 20 million yuan.
In 2008, the five-year national immunohistochemical quality control activity supported by Maixin Company was successfully completed.
In 2009, the trademark of Laoxin Company was awarded as "Famous Trademark of Fujian Province", and in the same year, the company won the honorary title of "High-tech Enterprise of Fujian Province" again.
In 2009, a special fund for pathology "Maixin Pathology" was established for the first time in China to fund scientific and technical personnel to conduct in-depth research, standardization and popularization of immunohistochemistry;
In 2009, the company successfully increased its capital again with a registered capital of 30 million yuan.